Search Results for: car t

On Wednesday, 27 October 2010, Brazil delivered the following intervention during the annual review of the Paragraph 6 system at the WTO TRIPS Council. The Brazilian intervention followed Canada’s detailed explanation of her use of the Paragraph 6 system in the Apotex/Rwanda case. The Brazilian intervention voiced concern over the future prospects of access to competitively priced second and third line ARVs raising questions as to whether the Paragraph 6 system would be economically viable for generic producers.

Continue Reading →

On Wednesday, 27 October 2010, the WTO TRIPS Council held its annual review of the Paragraph 6 System. IP-Watch has a link to the detailed program of the annual review. This annual review of the Paragraph 6 system lasted till around 8 PM Geneva time. More details of this closed door meeting will be provided in due course. Continue Reading →

Michèle Rivasi, a Member of the European Parliament, representing South East France for The Greens, has asked the European Commission: “Given the possible impacts of the inclusion of patents the agreement on access to medicines and on innovation, would the Commission consider accepting the exclusion of patents from the agreement as proposed by a number of ACTA negotiating parties?” The full text of her question follows:

Continue Reading →

As David Hammerstein of TACD has also blogged about here, Françoise Castex, a French Socialist MEP, has submitted this priority question about ACTA to the European Commission, asking the Commission to respond to the assertions by the USTR that ACTA wo Continue Reading →

(A PDF version of this is available here.)

Knowledge Ecology International

October 25, 2010

Letter to the European Parliament regarding ACTA

Continue Reading →

The October 2010 version of the ACTA text is inconsistent with several areas of U.S. law, and proposals for new laws in the areas of the reform of patent damages and access to orphaned copyrighted works. In particular, the obligations in the ACTA text do not incorporate many of the areas of limitations and exceptions to remedies found in U.S. law, and in the statutes of some other countries.

Continue Reading →

48th Series of Meetings of the World Intellectual Property Organization’s General Assemblies

Statement by H.E. Archbishop Silvano M. Tomasi, Permanent Representative of the Holy See to the United Nations and Other International Organizations in Geneva

at the 48th Series of Meetings of the World Intellectual Property Organization’s General Assemblies

Geneva, 21 September 2010

Mr. President,

Continue Reading →

Access to Orphan Works, and ACTA provisions on damages
KEI Policy Brief 2010: 1
20 October 2010

Introduction

Copyright is a term that in the United States describes the laws that regulate the use and distribution of “original works of authorship.” The types of activities and expressions protected by copyright have expanded over the years, particularly due to technology, but also due to the lobbying by various interested parties. The current systems of registration of copyrighted works in the United includes the following catagories:

Continue Reading →

In June of 2010, KEI was informed that representatives from the the United States Food and Drug Administration (FDA) had recently attended a summit in India on the issue of counterfeited and spurious medicines organized by the Partnership for Safe Medicines (PSM), a US-based organization with clear links to pharmaceutical corporate interests.

Continue Reading →